Glaukos (FRA:6GJ) Tariff Resilience Score: 5/10 (As of Jul. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:6GJ Glaukos Corp FRA:6GJ
81 GF Score
Price €140.00
GF Value €116.25
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Glaukos Tariff Resilience Score?

Glaukos FRA:6GJ +3.70% 81 Tariff Resilience Score is 5 as of Jul. 20, 2026. GuruFocus rates FRA:6GJ with a GF Score™ of 81/100 and a GF Value™ of €116.25 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 833 Medical Devices & Instruments companies, Glaukos ranks better than 79.23% on this metric.

Glaukos has the Tariff Resilience Score of 5, which implies that the company might have Average Resilient.

Glaukos has Glaukos faces moderate tariff risks due to its reliance on international suppliers for medical devices. While it has some pricing power, past impacts from medical device tariffs highlight its vulnerability.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Glaukos might have Average Resilient.

Glaukos  (FRA:6GJ) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Glaukos Tariff Resilience Score Related Terms

FRA:6GJ vs BIO, BRKR, PODD: Tariff Resilience Score Comparison

For the Medical Devices subindustry, Glaukos's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Glaukos Tariff Resilience Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Glaukos's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Glaukos's Tariff Resilience Score falls into.


FRA:6GJ
81GF Score
Glaukos Corp FRA:6GJ
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 5 mean?
Glaukos (FRA:6GJ) has a Tariff Resilience Score of 5 as of Jul. 20, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Glaukos ranks #173 out of 833 companies in the Medical Devices & Instruments industry, placing it in the top 20.8%.
Is Glaukos' Tariff Resilience Score too high?
Glaukos' current Tariff Resilience Score is 5. Based on the distribution chart, Glaukos ranks #173 out of 833 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Glaukos has a GF Score™ of 81/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Glaukos' Tariff Resilience Score compare to BIO and BRKR?
According to the Medical Devices & Instruments industry distribution chart, Glaukos ranks #173 out of 833 companies for Tariff Resilience Score. This places Glaukos in the top 21% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Medical Devices & Instruments company?
A good Tariff Resilience Score depends on the Medical Devices & Instruments industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. Glaukos's current Tariff Resilience Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Glaukos stock overvalued right now?
Based on GuruFocus' analysis, Glaukos (FRA:6GJ) is currently considered Modestly Overvalued. The stock's GF Value™ is €116.25, compared to a current price of €140.00 — trading 20.4% above its estimated fair value. The current Tariff Resilience Score is 5. Glaukos' overall GF Score™ is 81/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Glaukos (FRA:6GJ), the current Tariff Resilience Score is 5 as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Glaukos (FRA:6GJ) Overvalued in 2026?

Based on GuruFocus' analysis, Glaukos stock appears to be overvalued. The current stock price of €140.00 is trading 20.4% above its estimated GF Value™ of €116.25. GuruFocus considers Glaukos to be Modestly Overvalued.

Key valuation signals for FRA:6GJ:

  • Tariff Resilience Score: 5
  • GF Value™: €116.25 vs. price of €140.00 (20.4% above fair value)
  • GF Score™: 81/100 with 6 warning signs

No single metric tells the full story. See the FRA:6GJ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Glaukos Business Description

Other Exchanges GKOS:USA
Address One Glaukos Way, Aliso Viejo, CA, USA, 92656
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
81GF Score

Get the complete analysis for FRA:6GJ

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€140.00
Price
€116.25
GF Value